Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.

ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults, with an increasing proportion of patients aged ≥ 80 years. Although the POLARIX trial demonstrated improved progression-free survival with polatuzumab vedotin (Pola) combined with R-CHP (Pola-R-CHP), its applicability to very elderly patients remains unclear. A multicenter, retrospective, cohort study was conducted at seven hospitals in Japan, enrolling 172 previously untreated DLBCL patients who initiated Pola-R-CHP between August 1, 2022 and May 1, 2024. Patients were stratified by age (< 80 vs. ≥80 years). Initial dose intensity (IDI), average relative dose intensity (ARDI), treatment efficacy, and safety outcomes were evaluated. In patients aged ≥ 80 years (n = 44), the overall response rate (ORR) was 89.5%, comp

SUBMITTER: Yamada T 

PROVIDER: S-EPMC12619725 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature